Cures made in days,
not decades.
AlphaRose Therapeutics is building the world's first scalable platform for ultra-rare genetic medicines — starting with the diseases no one else will touch.
The Crisis No One Talks About
More than 200 million children worldwide are living with rare genetic diseases.
The vast majority — 95%— have zero approved treatments. Not because the science doesn't exist. Because the business model doesn't work.
Traditional drug development was built for blockbusters: big populations, big margins, long timelines. If your disease affects fewer than 500 people, you don't get a drug. You get a shrug.
That's not a scientific failure. It's a systems failure. And we're here to fix it.
Million children
Untreated
A father. A daughter.
A broken system.
AlphaRose was born from a promise. When Casey McPherson's daughter Rose was diagnosed with HNRNPH2 — an ultra-rare neurogenetic disease with no treatment and no roadmap — he was told there was nothing to be done.
He refused to accept that.
Casey assembled a team of world-class scientists, built a nonprofit (To Cure A Rose Foundation) and created the first proof-of-concept treatment for Rose's disease in under a year. Not in a decade. Not with hundreds of millions of dollars. In months, with a small team and relentless urgency.
That experience exposed a hard truth: the science to treat these children already exists. What doesn't exist are the systems, the business models, and the regulatory pathways to deliver it at scale.
AlphaRose Therapeutics was built to change that.
A platform that turns genetic diagnoses into treatments.
Argus
AI-driven target identification engine. Integrates public and proprietary gene datasets with machine learning to triage viable antisense targets. We've already screened over 300 monogenic CNS diseases and identified which ones are amenable to our platform.
MetaMorph
AI sequence design engine. Computationally predicts and optimizes ASO sequences for on-target efficacy, off-target safety, and toxicity profiles — replacing months of wet-lab screening with hours of computational design.
abcDNA
Proprietary backbone chemistry acquired from Alpha Anomeric SA (France). Eliminates sulfur linkages while preserving the phosphate structure required for gene silencing. The result: reduced immune activation, fewer off-target effects, and a cleaner safety profile.
SOT Caller
Epigenetic sense oligonucleotide platform. A first-of-its-kind "sense" technology that recruits endogenous transcription factors to precisely upregulate or downregulate gene expression — opening the door to durable treatments beyond traditional antisense knockdown.
Antisense oligonucleotides are the most deployable genetic medicine on the planet.
Gene therapies cost $1.5M+ per dose. They require viral vectors, complex manufacturing, and often can only be administered once. ASOs are different.
ASOs are synthetically manufactured, rationally designed, and chronically administered. They've already been approved by the FDA for multiple neurological diseases. Manufacturing costs are a fraction of gene therapy. And because they can be given repeatedly, they generate sustainable revenue per patient — not a one-time payment.
For ultra-rare diseases affecting 50 to 500 patients, ASOs are the only genetic modality where the economics actually work. That's not an opinion. That's math.
AlphaRose isn't betting on ASOs because they're trendy. We're betting on them because they're the only technology that can treat an individual child's disease and still build a viable business around it.
Programs in Motion
From computation to clinic.
Rosiphersen
ASOLead asset | PreclinicalHNRNPH2 (Bain Syndrome)
The first full application of the AlphaRose platform. Rosiphersen silences the toxic gain-of-function mutation in HNRNPH2. In vitro and in vivo non-GLP toxicology complete with no observable adverse effects. Demonstrates simultaneous HNRNPH2 knockdown and HNRNPH1 upregulation in human neurons. IND-enabling studies planned. Target: clinical trials with sub-$30M total development cost in 2-4 years.
ASO for Adrenoleukodystrophy
ASOPreclinicalAdrenoleukodystrophy
Lead candidates designed and computationally screened
SOT Caller for CDKL5 Deficiency
SOTPreclinicalCDKL5 (via CDKL2 upregulation)
Lead candidates designed and computationally screened
SOT Caller for Prion Disease
SOTPreclinicalPrion Disease
Lead candidates designed and computationally screened
ASO for VWD Type 2b
ASOPreclinicalVWD Type 2b
Lead candidates designed and computationally screened
This isn't charity. It's a new category of biotech.
Ultra-rare diseases aren't a niche — they're an untapped market. With orphan drug designation, 7 years of U.S. market exclusivity, 10 years in the EU, and the FDA's Pediatric Review Voucher (worth $75-100M alone), the regulatory incentives are enormous.
per patient per year
Our lead program, Rosiphersen, is projected at $300-600K per patient per year, with each patient generating an estimated $3.5M+ in lifetime revenue.
peak annual revenue
Peak annual product revenue for Rosiphersen alone: $100-700M. Every treatment we develop compresses our timelines, enriches our datasets, and proves out a repeatable model.
public benefit corporation
AlphaRose is a Public Benefit Corporation. That's not a compromise. It's a competitive advantage. It aligns every stakeholder — patients, investors, partners — around the same outcome.
We're building toward a future where a new ultra-rare medicine goes from genetic diagnosis to IND in six months — and where the platform itself becomes licensable. Treatments that work, delivered fast, at scale.
The People Behind This
Built by operators,
not observers.
Casey McPherson
Co-Founder & CEO
Rose's father. Built To Cure A Rose Foundation, assembled the team that created Rosiphersen in under a year, and drives the company's vision, culture, and fundraising.
Masako Nakamura
COO & President
Oversees clinical development, commercialization, and pipeline operations. Leads execution of Rosiphersen's path to market and manages grant funding strategy.
Robert Cabrera, Ph.D.
Chief Scientific Officer
Baylor College of Medicine. Leads all preclinical work across indications and oversees new technology platform development, including biomarker and toxicity programs.
Jeffrey Brown, Ph.D., MBA
Head of R&D
20+ years in preclinical drug development across Pfizer, BMS, Alexion, Voyager, and Wave Life Sciences. Has advanced multiple programs from concept to clinical candidate across RNA, AAV, and small molecule modalities.
We're not building a drug company. We're building the operating system for genetic medicine.
The endgame is a world where a child gets a genetic diagnosis and a personalized treatment in the same conversation. Where genetic medicine is a procedure, not a decade-long development program. Where cures are manufactured at the point of care.
Every piece of this technology exists today. No one has put it together. We are.
Rosiphersen
Proving the platform works from target to clinic.
Commercialization
Commercialization and pipeline expansion.
RNAR-1
A fully automated robotics lab that takes drug development from design to GMP manufacturing.
Global Scale
Licensing our AI platform (RINAE.AI) and our process to hospitals, biotechs, and pharma partners worldwide.
Get in Touch
We're Here to Help
Whether you have a project in mind, need guidance, or want to explore collaboration opportunities — reach out anytime. Our team will respond quickly and provide everything you need to move forward.